Ranibizumab treat-and-extend as effective as monthly injections in wet AMD

The CANTREAT trial found a treat-and-extend strategy with ranibizumab for patients with neovascular age-related macular degeneration was not worse than treatment with monthly injections after 2 years, according to a study.
“Our goal in treating macular degeneration, the most common cause of blindness in the Western world, is to maximize visual gains and minimize the burden of treatment and visits on patients and their families. This most recent Canadian Treat-and-Extend study (CANTREAT) publication shows definitively that patients randomized to a treat-and-extend regimen had similar

Full Story →